Sentences with phrase «in early prostate cancer»

«Shorter, intensive radiation can be recommended in early prostate cancer.»

Not exact matches

Buffett has said that he remains in good health and his doctors never considered the prostate cancer life - threatening because it was caught early.

He was diagnosed as having prostate cancer in the early»90s (the cancer is in remission) and underwent quintuple bypass surgery in July 2001, but is as fit as most men 20 years his junior.

But that was the unnerving conclusion of a draft report released last week by the National Toxicology Program, part of the National Institutes of Health, which said exposure to BPA may be linked to breast cancer, prostate cancer and early puberty in girls.

(CNN)-- Connecticut Democrat Sen. Chris Dodd was released Saturday from Memorial Sloan - Kettering Cancer Center after surgery to treat early stage prostate cancer, Dodd's office said in a statCancer Center after surgery to treat early stage prostate cancer, Dodd's office said in a statcancer, Dodd's office said in a statement.

An implant of genetically engineered skin cells has been designed to grow darker in colour when it detects early breast, prostate and colon cancers

A new screening tool for prostate cancer, the prostate - specific antigen test, enabled doctors to detect it earlier in more men, and patients were flocking to hospitals for low doses of conventional photon radiation.

While prostate cancer is relatively easy to treat in its early stages, it is prone to metastasis and can quickly become deadly.

«An estimated 220,000 men are expected to be newly diagnosed with prostate cancer each year in the United States, and the majority will have early - stage disease at low risk for recurrence,» Lee said.

«Targeting multiple biomarkers could potentially allow us to identify prostate cancer at its early stages as well as after metastasis in one scan.»

«This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer,» stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

For prostate cancer, the key reason for the fall in death rates is improved management and treatment, with a possible role played by screening and early diagnosis.

Edward Messing, the senior author of the study, says that PSA is capable of detecting the disease earlier, which could, in theory lead to fewer deaths from prostate cancer.

In 2009 the nongovernmental Institute of Medicine (IOM) released a list of 100 disorders, including lower back pain, atrial fibrillation, and early prostate cancer, that it says require research analyzing which treatments work best for different groups of patients.

Early epidemiological studies suggested that men who ate diets rich in tomato products enjoyed lower than average rates of prostate cancer, and lycopene was identified as the likely reason.

The five types of cancers analyzed in this study have screening methods that allow for detection at an early stage, though in some instances, debate remains over efficacy and appropriate use: mammography for breast cancer, colonoscopy for colorectal cancer, Pap smear and / or HPV test for cervical cancer, spiral computed tomography or CT for lung cancer, and PSA test for prostate cancer.

«Less prostate cancer screening may delay treatment for earlier onset cancers: More advanced cancers are being found in fewer needle biopsies, say investigators.»

«The Prostate Health Index is a significant addition to our comprehensive menu of advanced clinical evidence ‐ based blood tests that aid in early cancer detection.»

«New three - in - one blood test opens door to precision medicine for prostate cancer: Test picks out men for treatment, detects early signs of resistance and monitors cancer's evolution over time.»

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

The study suggests that efforts are needed to reduce racial disparities in prostate cancer care in order to provide earlier treatment for African Americans.

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine.

This rise is particularly troubling, the authors said, because men in this age group are believed to benefit most from prostate cancer screening and early treatment.

They and colleagues from Johns Hopkins and University Medical Centre Utrecht had earlier discovered that a protein called DDX3 appears to be «dysregulated» in many cancers, including breast, lung, colorectal, sarcoma and prostate.

The study involved 10 men in their early 60s with prostate cancer, who were asked to follow a strict healthy - living regime rather than take a course of drugs.

Early exposure to BPA (bisphenol A)-- an additive commonly found in plastic water bottles and soup can liners — causes an increased cancer risk in an animal model of human prostate cancer, according to University of Illinois at Chicago researcher Gail Prins.

Published in Urology in April 2007 by Johns Hopkins University researcher Robert Getzenberg and his team, the paper reported that a novel protein in blood could be used as a sensitive test for detecting early prostate cancer.

«Since the difference in the number of men diagnosed with prostate cancer is related to how many men undergo PSA testing, we think our data shows that PSA testing and early treatment is related to a modest decrease in risk of prostate cancer death,» says Håkan Jonsson statistician and senior author of the study.

«Our results show that prostate cancer mortality was 20 percent lower in counties with the highest incidence of prostate cancer, indicating an early and rapid uptake of PSA testing, compared with counties with a slow and late increase in PSA testing,» says Pär Stattin, lead investigator of the study.

«While each of these genes was independently associated with metastatic prostate cancer, they have never been studied together in the context of early detection of patients with prostate cancer that will relapse after localized therapy with curative intent, «according to the authors, led by Leigh Ellis, PhD, in the Dana - Farber Department of Oncologic Pathology.

They found that cases of ovarian cancer linked to genes inherited from the paternal grandmother had an earlier age - of - onset than cases linked to maternal genes, and were also associated with higher rates of prostate cancer in fathers and sons.

A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons.

Similarly, a prostate - specific antigen (PSA) test has revolutionised early diagnosis for this cancer in the US.

It recognises the four most common types of cancer — prostate, lung, colon and breast cancer — at a very early stage, namely when the level of calcium in the blood is elevated due to the developing tumour.

Like pervasive hypertension, some cancers, such as prostate and breast, tend to occur earlier and be more aggressive in blacks than whites, said Dr. Edward J. Kruse, chief of surgical oncology at MCG and the Georgia Cancer Center.

The decrease in quality of life from early AMD is similar to that caused by HIV, and with advanced AMD, similar to that of metastatic prostate cancer with uncontrollable pain.

Cancers of the breast, prostate, colorectal system, liver and kidney as well as multiple myeloma, a cancer of the plasma cells that make antibodies to fight viruses and bacteria, strike earlier, deadlier and more often in some racial and ethnic groups, the National Cancer Institute has cancer of the plasma cells that make antibodies to fight viruses and bacteria, strike earlier, deadlier and more often in some racial and ethnic groups, the National Cancer Institute has Cancer Institute has shown.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, associate professor in the UNC School of Medicine Department of Radiation Oncology.

The paper, «MR Imaging - guided Focal Laser Ablation for Prostate Cancer: Phase I Trial,» appears as an early release in Radiology.

«One type of PARP inhibitor has already shown promise in a patient with advanced prostate cancer, and the early results are encouraging.»

Researchers, funded by Cancer Research UK, from the Section of Gene Function and Regulation and the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR), have pinpointed early genetic changes that lead to cancer in mice lacking the BRCA2 gene in their prostate Cancer Research UK, from the Section of Gene Function and Regulation and the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research (ICR), have pinpointed early genetic changes that lead to cancer in mice lacking the BRCA2 gene in their prostate Cancer Research Centre at The Institute of Cancer Research (ICR), have pinpointed early genetic changes that lead to cancer in mice lacking the BRCA2 gene in their prostate Cancer Research (ICR), have pinpointed early genetic changes that lead to cancer in mice lacking the BRCA2 gene in their prostate cancer in mice lacking the BRCA2 gene in their prostate gland.

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.

Founded in 2014 by world renowned cancer researchers, Drs. Charles Sawyers and Scott Lowe, from Memorial Sloan Kettering Cancer Center, the company is currently taking aim at clinical relapse in hormone - driven cancers such as prostate, with the aim or producing its first clinical candidate by earlycancer researchers, Drs. Charles Sawyers and Scott Lowe, from Memorial Sloan Kettering Cancer Center, the company is currently taking aim at clinical relapse in hormone - driven cancers such as prostate, with the aim or producing its first clinical candidate by earlyCancer Center, the company is currently taking aim at clinical relapse in hormone - driven cancers such as prostate, with the aim or producing its first clinical candidate by early 2016.

Many elderly men may undergo unnecessary prostate cancer screenings while men in their early fifties, who are more likely to benefit from early diagnosis and treatment, do not, according to a new study published March 28 in the Journal of Clinical Oncology.

March 28, 2011 Many elderly men undergo unnecessary PSA screenings Many elderly men may undergo unnecessary prostate cancer screenings while men in their early fifties, who are more likely to benefit from early diagnosis and treatment, do not, according to a new study published March 28 in the Journal of Clinical Oncology.

Since then, diagnoses of early prostate cancer in American men aged 50 and older dropped by 19 percent between 2011 and 2012 and by another 6 percent the following year, said lead researcher Dr. Ahmedin Jemal.

THURSDAY, Aug. 18, 2016 (HealthDay News)-- Diagnoses of early prostate cancer continue to decline in the United States, following the U.S. Preventive Services Task Force recommendation against routine screening for the disease, researchers report.

They found that from 2012 to 2013, early prostate cancer diagnosis rates per 100,000 men dropped from 356.5 to 335 in men aged 50 to 74.

Aspirin has been shown to reduce the risk of colorectal cancer and precancerous polyps, and in a pair of studies published earlier this year, researchers found that people were less likely to develop or die from cancers — including those of the lung, prostate, and bladder — if they took aspirin daily.